5/25, 1:33 PM (Source: TeleTrader)
more TeleTrader news

MSN Laboratories to start third phase of its COVID treatment

MSN Laboratories revealed on Tuesday it is about to begin the third and last phase of clinical trials for its COVID-19 treatment Molnupiravir after receiving approval from Indian authorities on May 19.

According to the regulatory filing, MSN Laboratories will test the drug on more than 2,400 subjects infected with the COVID-19 across 40 different sites in India.

Natco Pharma yesterday also confirmed it has begun the third trial phase of Molnupiravir, prompting the company's shares to reach a new record-high.

Breaking the News / ND